Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008

Clinical Drug Investigation

Volumn 33, Issue 9, 2013, Pages 647-652

  Tsai, Ching Piao ^a   Lee, Charles Tzu Chi ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE MODIFYING THERAPY; FEMALE; FOLLOW UP; GEOGRAPHY; HEALTH INSURANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; MULTIPLE SCLEROSIS; PHARMACEUTICAL CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; RURAL AREA; SCHOOL CHILD; SOCIAL STATUS; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; URBAN AREA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; PROPORTIONAL HAZARDS MODELS; TAIWAN; TIME FACTORS;

EID: 84883243238     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0108-7     Document Type: Article

References (20)

1. Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601-9.
2. Khan O, Bao F, Shah M, et al. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. J Neurol Sci. 2012;312(1-2):7-12.
3. Marta M, Giovannoni G. Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. CNS Neurol Disord Drug Targets. 2012;11(5):610-23.
4. Elhami SR, Mohammad K, Sahraian MA, et al. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. Neuroepidemiology. 2011;36(3):141-7.
5. Benito-Leon J. Are the prevalence and incidence of multiple sclerosis changing? Neuroepidemiology. 2011;36(3):148-9.
6. Hirst C, Ingram G, Pickersgill T, et al. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry. 2009;80(4):386-91.
7. Koutsouraki E, Costa V, Baloyannis S. Epidemiology of multiple sclerosis in Europe: a review. Int Rev Psychiatry. 2010;22(1):2-13.
8. Lai CH, Tseng HF. Population-based epidemiological study of neurological diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis. Neuroepidemiology. 2009;33(3):247-53.
9. Cheng Q, Miao L, Zhang J, et al. A population-based survey of multiple sclerosis in Shanghai, China. Neurology. 2007;68(18):1495-500.
10. Lau KK, Wong WW, Sheng B, et al. The clinical course of multiple sclerosis patients in Hong Kong. J Neurol Sci. 2008;268(1-2):78-82.
11. Iuliano G, Napoletano R. Prevalence and incidence of multiple sclerosis in Salerno (southern Italy) and its province. Eur J Neurol. 2008;15(1):73-6.
12. Noonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis. 2010;7(1):A12.
13. Ragonese P, Aridon P, Mazzola MA, et al. Multiple sclerosis survival: a population-based study in Sicily. Eur J Neurol. 2010;17(3):391-7.
14. Poser S, Kurtzke JF, Poser W, et al. Survival in multiple sclerosis. J Clin Epidemiol. 1989;42(2):159-68.
15. Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51-61.
16. GryttenTorkildsen N, Lie SA, Aarseth JH, et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler. 2008;14(9):1191-8.
17. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain. 2004;127(Pt 4):844-50.
18. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology. 2012;78(17):1315-22.
19. Veugelers PJ, Fisk JD, Brown MG, et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult Scler. 2009;15(11):1286-94.
20. Wong J, Gomes T, Mamdani M, et al. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci. 2011;38(3):429-33.